Physicians' Academy for Cardiovascular Education
Experts in dialogue - LDL-c goal attainment in high risk patients

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD

Outcomes with P2Y12 inhibitors after PCI according to CYP2C19 genotype

5' education - Apr. 12, 2021 - Danny Claassens, MD

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: how are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD

Clinical outcomes with low dose vs. high dose DOAC in AF

5' education - Mar. 30, 2021 - Prof. Jan Steffel, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Personalized antithrombotic therapy after PCI

5' education - Mar. 17, 2021 - Niels van der Sangen, MD

Ketones as a possible therapeutic option for patients with CVD

10' education - Mar. 16, 2021 - B. Daan Westenbrink MD, PhD

GLP-1RA induces weight loss in adults with overweight or obesity

5' education - Mar. 2, 2021 - Prof. Robert Kushner, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

Rise in ANP might mediate benefits of ARNI in HFrEF

10' education - Feb. 16, 2021 - Sean Murphy, MD

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD

No decrease in thrombotic complications in second COVID-19 wave

5' education - Feb. 4, 2021 - Fleur Kaptein, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Older adults should also be treated to lower LDL-c

5' education - Jan. 18, 2021 - Prof. Børge Nordestgaard, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Registry data of PCKS9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.

Modified CHADS2 shows best predictive performance for stroke across spectrum of kidney function

Literature - Apr. 13, 2021 - De Jong Y et al. - Eur Heart J. 2021

This study validated six risk scores for ischemic stroke in patients with AF across the spectrum of kidney function. The Modified CHADS2 score showed most consistent predictive performance in all kidney function categories.

Registry data of PCSK9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD
Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these.

Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.

Comparison of P2Y12 inhibitors after PCI in patients without CYP2C19 LoF allele

Literature - Apr. 12, 2021 - Claassens DMF, et al. - Circ Cardiovasc Interv. 2021

This subanalysis of the POPular Genetics trial showed that non-carriers of CYP2C19*2 or *3 LoF alleles treated with clopidogrel after primary PCI had less bleeding and similar thrombotic risk compared to patients on ticagrelor or prasugrel.

Outcomes with P2Y12 inhibitors after PCI according to CYP2C19 genotype

5' education - Apr. 12, 2021 - Danny Claassens, MD
Danny Claassens presents the results of a prespecified subanalysis of the POPular Genetics trial, which focused on trombotic and bleeding outcomes in //CYP2C19// genotype subgroups treated with clopidogrel or standard ticagrelor/prasugrel after PCI

Danny Claassens presents the results of a prespecified subanalysis of the POPular Genetics trial, which focused on trombotic and bleeding outcomes in CYP2C19 genotype subgroups treated with clopidogrel or standard ticagrelor/prasugrel after PCI.

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD
Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

ApoB and non-HDL-c are better markers of residual risk than LDL-c in statin-treated patients

Literature - Apr. 7, 2021 - Johannesen CDL et al. - J Am Coll Cardiol. 2021

Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.

FDA approves PCSK9 inhibitor for patients with HoFH

News - Apr. 6, 2021

The PCSK9 inhibitor alirocumab has been approved by the US Food and Drug Administration (FDA) as an adjunct to other LDL-c lowering therapies for the treatment of adult patients with homozygous familial hypercholesterolemia.

Elevated non-HDL-c during adolescence, young- and mid-adulthood associated with CAC

Literature - Apr. 6, 2021 - Armstrong MK, et al. - JAMA Cardiol. 2021

Elevated non-HDL-c during adolescence, young- and mid-adulthood was associated with the presence of CAC in mid-adulthood. Adolescent non-HDL-c levels showed the strongest association with CAC in mid-adulthood.

Clinical resemblance of heparin-induced thrombocytopenia in some cases after COVID-19 vaccination

Literature - Apr. 6, 2021 - Greinacher A et al. - Research Square 2021 (NOT PEER-REVIEWED)

Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD
Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Agenda